Rationale for the Development of the Fact-N: A Neutropenia-Specific Quality-of-Life Tool

2.50
Hdl Handle:
http://hdl.handle.net/10755/165409
Category:
Abstract
Type:
Presentation
Title:
Rationale for the Development of the Fact-N: A Neutropenia-Specific Quality-of-Life Tool
Author(s):
Anderson, N.; Cella, D.; Calhoun, E.; Novak, K.; Chang, C. H.; Welshman, E.
Author Details:
N. Anderson, Northwestern Medical Faculty Foundation, Inc., Chicago, Illinois, USA; D. Cella; E. Calhoun; K. Novak; C. H. Chang; E. Welshman
Abstract:
Quality-of-life (QOL) is an increasingly important measure for assessing cancer treatments. QOL is affected by changes in physical, functional, emotional, and social well-being. Clearly, chemotherapy is expected to produce changes in QOL, and validated tools that capture QOL changes have been used in clinical trials. One such tool, the FACT-G (Functional Assessment of Cancer Therapy – General), uses a 5-point scale (“0” means “not at all” while “4” means “very much”) to assess how patients view their current condition, with questions regarding specific symptoms, concerns, and emotions. The FACT-N is a neutropenia-specific QOL tool currently being developed and validated as a companion tool to the 27-item FACT-G. Validation is an important step in the development of a QOL tool, because it indicates that the survey questions capture meaningful and relevant issues specific to the topic (in this case, neutropenia) and that the tool can reasonably be expected to produce accurate responses when used in different studies. The FACT-N questions were developed after reviewing medical literature and conducting interviews with 10 clinicians, 25 patients with cyclic neutropenia, 25 with congenital neutropenia, and 25 patients with chemotherapy-induced neutropenia (CIN). Fifty-one questions were initially generated. Twelve experts rated the items for clarity, relevance, and redundancy and identified 19 items that came to comprise the FACT-N. In order to test reliability and validity, the FACT-N was administered to 60 chemotherapy patients. All patients completed the FACT-N at baseline, and those experiencing neutropenia received the survey again. All patients completed the FACT-N with the last chemotherapy cycle. The results suggest that the FACT-N has internal consistency, meaning that the items measure the underlying concept. Additionally, two subscales, a 7-item Fatigue subscale and a 4-item Worry subscale, exist within the FACT-N. Preliminary data on the relationship of FACT-N responses to neutrophil count changes during chemotherapy will be presented. In summary, the FACT-N represents the first neutropenia-specific QOL tool. It will ultimately be incorporated into oncology clinical trials, providing oncology nurses with a better understanding of the overall impact of chemotherapy on patient’s lives and the effectiveness of interventions designed to minimize this impact.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2003
Conference Name:
28th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Denver, Colorado, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleRationale for the Development of the Fact-N: A Neutropenia-Specific Quality-of-Life Toolen_GB
dc.contributor.authorAnderson, N.en_US
dc.contributor.authorCella, D.en_US
dc.contributor.authorCalhoun, E.en_US
dc.contributor.authorNovak, K.en_US
dc.contributor.authorChang, C. H.en_US
dc.contributor.authorWelshman, E.en_US
dc.author.detailsN. Anderson, Northwestern Medical Faculty Foundation, Inc., Chicago, Illinois, USA; D. Cella; E. Calhoun; K. Novak; C. H. Chang; E. Welshmanen_US
dc.identifier.urihttp://hdl.handle.net/10755/165409-
dc.description.abstractQuality-of-life (QOL) is an increasingly important measure for assessing cancer treatments. QOL is affected by changes in physical, functional, emotional, and social well-being. Clearly, chemotherapy is expected to produce changes in QOL, and validated tools that capture QOL changes have been used in clinical trials. One such tool, the FACT-G (Functional Assessment of Cancer Therapy – General), uses a 5-point scale (“0” means “not at all” while “4” means “very much”) to assess how patients view their current condition, with questions regarding specific symptoms, concerns, and emotions. The FACT-N is a neutropenia-specific QOL tool currently being developed and validated as a companion tool to the 27-item FACT-G. Validation is an important step in the development of a QOL tool, because it indicates that the survey questions capture meaningful and relevant issues specific to the topic (in this case, neutropenia) and that the tool can reasonably be expected to produce accurate responses when used in different studies. The FACT-N questions were developed after reviewing medical literature and conducting interviews with 10 clinicians, 25 patients with cyclic neutropenia, 25 with congenital neutropenia, and 25 patients with chemotherapy-induced neutropenia (CIN). Fifty-one questions were initially generated. Twelve experts rated the items for clarity, relevance, and redundancy and identified 19 items that came to comprise the FACT-N. In order to test reliability and validity, the FACT-N was administered to 60 chemotherapy patients. All patients completed the FACT-N at baseline, and those experiencing neutropenia received the survey again. All patients completed the FACT-N with the last chemotherapy cycle. The results suggest that the FACT-N has internal consistency, meaning that the items measure the underlying concept. Additionally, two subscales, a 7-item Fatigue subscale and a 4-item Worry subscale, exist within the FACT-N. Preliminary data on the relationship of FACT-N responses to neutrophil count changes during chemotherapy will be presented. In summary, the FACT-N represents the first neutropenia-specific QOL tool. It will ultimately be incorporated into oncology clinical trials, providing oncology nurses with a better understanding of the overall impact of chemotherapy on patient’s lives and the effectiveness of interventions designed to minimize this impact.en_GB
dc.date.available2011-10-27T12:18:01Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:18:01Z-
dc.conference.date2003en_US
dc.conference.name28th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationDenver, Colorado, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.